On January 22, 2026, 4D Molecular Therapeutics exchanged common stock for pre-funded warrants, with RA Capital exchanging 4,850,000 shares and BVF exchanging 1,750,000 shares. As of January 23, 2026, the company had 51,007,874 shares outstanding, excluding 16,935,665 shares issuable upon warrant exercise.